Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2025-06-26 00:00:00 ET · period of report 2025-06-24 · accession 0001439222-25-000063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-06-26 | 2025-06-24 | AGIO | Goff Brian | CEO, Dir | M - OptEx | $0.00 | +38.3K | 117.9K | +48% | $0 |
| DM | 2025-06-26 | 2025-06-24 | AGIO | Goff Brian | CEO, Dir | S - Sale+OE | $33.54 | -18.7K | 111.9K | -14% | -$627.2K |
| DM | 2025-06-26 | 2025-06-24 | AGIO | Goff Brian | CEO, Dir | M - OptEx | $0.00 | -38.3K | 12.8K | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2025-06-24 | M | A | 12,750 | $0.00 | 118,151 | D | — | — | |
| 2 | Common | Common stock | 2025-06-24 | S | D | 12,471 | $33.54 | 105,401 | D | — | — | |
| 3 | Common | Common stock | 2025-06-24 | S | D | 6,229 | $33.54 | 111,922 | D | — | — | |
| 4 | Common | Common stock | 2025-06-24 | M | A | 25,527 | $0.00 | 117,872 | D | — | — | |
| 5 | Derivative | Performance share units | 2025-06-24 | M | D | 25,527 | $0.00 | 51,056 | D | — · — to — | 25,527 Common stock | (F3) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F4) The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| 6 | Derivative | Performance share units | 2025-06-24 | M | D | 12,750 | $0.00 | 12,750 | D | — · — to — | 12,750 Common stock | (F3) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F5) The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |